OS Therapies Inc (OSTX) stock
OSTXNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.74−0.01 (-0.68%)
Close on Nov 13, 2026Market cap $34.36MP/E –Yield –
OS Therapies r&d expenses
Research and development expenses are spending on new products and technology.
OS Therapies's R&D Expenses for the twelve months ending Jun 30, 2026 was $25.98M, up 341.1% year over year. For fiscal 2025 it was $16.36M, up 476.3% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.36M | +476.3% |
| FY2024 | Dec 31, 2024 | $2.84M | -11.7% |
| FY2023 | Dec 31, 2023 | $3.22M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $6.07M | +143.0% |
| Q1 FY2026 | Mar 31, 2026 | $7.35M | +461.6% |
| Q4 FY2025 | Dec 31, 2025 | $8.80M | +910.6% |
| Q3 FY2025 | Sep 30, 2025 | $3.76M | +210.3% |
| Q2 FY2025 | Jun 30, 2025 | $2.50M | +530.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.31M | +261.8% |
| Q4 FY2024 | Dec 31, 2024 | $870.47K | -14.6% |
| Q3 FY2024 | Sep 30, 2024 | $1.21M | +166.3% |
| Q2 FY2024 | Jun 30, 2024 | $396.57K | -60.1% |
| Q1 FY2024 | Mar 31, 2024 | $361.81K | -52.0% |
| Q4 FY2023 | Dec 31, 2023 | $1.02M | – |
| Q3 FY2023 | Sep 30, 2023 | $454.51K | – |
| Q2 FY2023 | Jun 30, 2023 | $992.90K | – |
| Q1 FY2023 | Mar 31, 2023 | $753.78K | – |
See a number that looks wrong?